Biotech

"Senator Baucus has shown tremendous leadership in Montana in the area of assisting small businesses to create more job opportunities, especially in challenging economic times." Ateris co-owners Jon Nagy

"We are extremely pleased with the opportunity to share the important results from this carefully designed proof-of-concept, multi-center challenge study. Challenge studies are rigorous tests and we have established for the first time that immunized subjects can reduce their risk of norovirus illness by receiving a vaccine," said Donald P. Beeman, Chief Executive Officer.

"Norovirus infections are recognized as a widespread problem that can have very serious consequences," said Donald P. Beeman, CEO of LigoCyte.

As you know, Senator Max Baucus championed the creation of this new program to support biomedical research by small firms. The program provides tax credits and grants to small firms that show significant potential to produce new and cost-saving therapies.

Insofar as medical innovation is the future of health care, however, we are now seeing that health care plays a central role in the future of our economy.

The guidance released today by the Internal Revenue Service (IRS) describes the process by which firms can apply to have their research projects certified as eligible for the credit.

In contrast to rumors that have been floating around, the program is not set up on a “first come, first served” basis.

Companies working on projects that have "significant potential" to produce new drugs, find a cure for cancer, or address unmet medical needs can apply for up to a $5-million share of the funds.

The average pay for participants is $25 per hour; studies can pay up to $500 total.

Few people in Seattle know much about Hood’s nonprofit research center, and it puzzles more than a few biologists, but it has definitely been on a roll the past couple years.